Citrulline inhibits Clostridioides difficile infection with anti-inflammatory effects.|https://dx.doi.org/10.1016/j.jcmgh.2025.101474
Extraintestinal Clostridium difficile infection presenting as spontaneous bacterial peritonitis.|https://dx.doi.org/10.1136/bcr-2024-262106
Radiological Risk Factors for Osteochondral Fractures in Patients With First-Time and Recurrent Patellar Instability: Data From the JUPITER Cohort.|https://dx.doi.org/10.1177/03635465251315170
Corrigendum to "Live Biotherapeutic Products for the Prevention of Recurrent Clostridioides difficile Infection".|https://dx.doi.org/10.1177/10600280241310646
Integrating bulk RNA-seq and scRNA-seq data to explore diverse cell death patterns and develop a programmed cell death-related relapse prediction model in pediatric B-ALL.|https://dx.doi.org/10.1038/s41598-025-86148-y
Identification of two glycosyltransferases required for synthesis of membrane glycolipids in Clostridioides difficile.|https://dx.doi.org/10.1128/mbio.03512-24
Clinical Characteristics and Outcomes of Clostridioides difficile Infection in Cancer Patients From a Tertiary Care Hospital.|https://dx.doi.org/10.7759/cureus.77616
Higher disease activity of inflammatory bowel disease predisposes to Clostridioides difficile infection.|https://dx.doi.org/10.1177/17562848251318292
Fecal microbiota transplantation for Clostridioides difficile infection in a peritoneal dialysis patient: A case report.|https://dx.doi.org/10.1177/08968608251316165
Clinical and economic outcomes associated with fidaxomicin in comparison to vancomycin, metronidazole, and FMT: A systematic literature review.|https://dx.doi.org/10.1097/MD.0000000000039219
Clostridioides difficile major toxins remodel the intestinal epithelia, affecting spore adherence/internalization into intestinal tissue and their association with gut vitronectin.|https://dx.doi.org/10.1101/2025.01.29.635439
Efficacy and the underlying mechanisms of berberine in treatment of recurrent Clostridioides difficile infection.|https://dx.doi.org/10.1016/j.ijantimicag.2025.107468
Comparative effectiveness of different therapies for Clostridioides difficile infection in adults: a systematic review and network meta-analysis of randomized controlled trials.|https://dx.doi.org/10.1016/j.lanepe.2024.101151
Advancements in the Pathogenesis, Diagnosis, and Therapeutic Implications of Intestinal Bacteria.|https://dx.doi.org/10.3390/cimb47020106
Body mass index changes after fecal microbiota transplantation for recurrent Clostridioides difficile infection.|https://dx.doi.org/10.1177/17562848251321121
Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.|https://dx.doi.org/10.1002/advs.202413197
In vitro validation concept for lyophilized fecal microbiota products with a focus on bacterial viability.|https://dx.doi.org/10.1007/s11274-025-04291-0
Development of live biotherapeutic products: a position statement of Asia-Pacific Microbiota Consortium.|https://dx.doi.org/10.1136/gutjnl-2024-334501
Case report of clostridium difficile infection after rectal resection with ileostomy.|https://dx.doi.org/10.1186/s12957-025-03713-5
Effects of clinical donor characteristics on the success of faecal microbiota transplantation for patients in Denmark with Clostridioides difficile infection: a single-centre, prospective cohort study.|https://dx.doi.org/10.1016/j.lanmic.2024.101034
